
Roche haemophilia therapy cuts bleed rate by 87%
pharmafile | June 26, 2017 | News story | Research and Development, Sales and Marketing | Roche, haemophilia
Roche has revealed new data on its investigational haemophilia therapy ACE910 (emicizumab) which shows an 87% reduction in bleed rate among patients who had become resistant to conventional treatment.
Resistance to treatment can disrupt attempts to control bleeding as a result of haemophilia, a disorder which prevents the blood for clotting as it should. The results of Roche’s late-stage trial showed that no treated bleeds were experienced by 62.9% of those using the drug, compared to 5.6% in patients treated with bypassing agents.
With this data, the company is hoping the treatment can fight off Novo Nordisk and Shire for a share of the haemophilia market – a space worth $11 billion per year. Analysts are valuing Roche’s new drug at $5 billion on the back of the new data.
However, the results also showed that repeated high doses of bypassing agents as a treatment for breakthrough bleeds led to adverse events including microangiopathy – the trial was even marked by the death of one patient – Roche said this was due to the participant refusing a blood transfusion on religious grounds.
Despite this, Roche plans to file for US regulatory approval later this year.
Matt Fellows
Related Content

Roche receives CE Mark for blood test to help rule out Alzheimer’s
Roche has been granted CE Mark approval for its Elecsys pTau181 test, the first in …

Roche candidate shows early promise for treating haemophilia A
Roche has announced encouraging early results from its phase 1/2 trial of NXT007, an investigational …

Novo Nordisk presents promising findings for haemophilia treatment
Novo Nordisk has presented data indicating that a direct switch to Mim8 (denecimig) prophylaxis treatment …






